Pharma News

Researchers have found a way to make an existing drug used to treat breast, lung and pancreatic cancers effective in small dosage, thereby reducing its usage and associated side effects in course of the treatment.

The risk of developing colorectal cancer in obese people is about 50 percent greater compared to the risk in lean people, says new research.

Obesity has an association with the formation of blood clots in the veins of children and adolescents, says a new study.

The National Institute of Cholera and Enteric Diseases (NICED), a premier institute under the Indian Council of Medical Research (ICMR), is in talks with the West Bengal government to introduce a cholera vaccine ahead of the peak season as a preventive measure.

The National Institute of Cholera and Enteric Diseases (NICED) here on Friday inked a deal with the Bengal Chamber of Commerce and Industry (BCCI) to undertake cutting-edge research on enteric diseases including hepatitis C, and see through translation of research outputs for community outreach.

The Zika virus, spread by a day-biting mosquito and possibly linked to serious birth defects in Brazil, has the potential to spread within the Americas, including parts of the US, researchers have warned. The Zika virus, native to parts of Africa and Asia, has for the first time been introduced into the Americas where it is spreading locally among people who have not travelled abroad.

A 59-year-old man was the first case dying of implications after infection from a mutated strain of influenza, Greek authorities announced on Thursday.

[adsense:336x280:8701650588]

CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced that China’s Food and Drug Administration (CFDA) has accepted for review its import drug registration application for MARQIBO® (vinCRIStine sulfate LIPOSOME injection).

Immunovaccine Inc, a clinical stage vaccine and immunotherapy company, announced U.S. Food and Drug Administration (FDA) and Health Canada clearance to initiate a clinical study of DPX-Survivac in combination with low-dose cyclophosphamide and epacadostat. Resulting from a recently announced collaboration between Immunovaccine and Incyte Corporation (“Incyte”), the Phase 1b clinical trial will assess the safety and effectiveness of Immunovaccine’s novel T cell activating therapy, DPX-Survivac, along with Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), and low-dose cyclophosphamide in patients with recurrent ovarian cancer who have measurable disease. Immunovaccine anticipates starting the trial, which Incyte will co-fund under the terms of the agreement between the two companies, by Q2 2016.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted AbbVie’s supplemental New Drug Application (sNDA) and granted priority review for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin (RBV) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) and compensated cirrhosis (Child-Pugh A). The current dosing recommendation for patients with GT1b and compensated cirrhosis is to administer RBV with VIEKIRA PAK for 12 weeks.